关于无锡药明康德新药开发股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 如实编制和对外披露汇总表并确保其真实性、合法性及完整性是贵公司管理层的责任。 我们对汇总表所载资料与本所审计贵公司 2024 年度财务报表时所复核的会计资料和经审计的 财务报表的相关内容进行了核对，在所有重大方面没有发现不一致。除了按照中国注册会计 师审计准则对贵公司实施 2024 年度财务报表审计中所执行的与关联方交易有关的审计程序外， 我们并未对汇总表所载资料执行额外的审计程序。 目 录 1、 专项审计报告 2、 附表 委托单位：无锡药明康德新药开发股份有限公司 审计单位：德勤华永会计师事务所(特殊普通合伙) 关于无锡药明康德新药开发股份有限公司 控股股东、实际控制人及其他关联方资金占用情况的专项说明 德师报(函)字(25)第 Q00285 号 无锡药明康德新药开发股份有限公司董事会： 我们接受委托，依据中国注册会计师审计准则审计了无锡药明康德新药开发股份有限公 司(以下简称"贵公司") 2024 年 12 月 31 日合并及母公司资产负债表、2024 年度合并及母公司利 润表、合并及母公司现金流量表、合并 ...

关于无锡药明康德新药开发股份有限公司 会计政策变更的专项说明 德师报(函)字(25)第Q00302号 无锡药明康德新药开发股份有限公司全体股东： 根据上海证券交易所《上市公司日常信息披露工作备忘录第一号——临时公告格式指引 第九十三号——会计差错更正、会计政策或会计估计变更》及《企业会计准则第 28 号——会 计政策、会计估计变更和差错更正》的要求，无锡药明康德新药开发股份有限公司(以下简称 "药明康德")董事会编制了后附的《无锡药明康德新药开发股份有限公司董事会关于会计政 策变更的专项说明》(以下简称"情况说明")。 如实编制和对外披露情况说明并确保其真实性、合法性及完整性是药明康德的责任。我 们对情况说明所载资料进行了检查，未发现情况说明在所有重大方面存在不符合企业会计准 则的情况。 本专项说明仅供药明康德向上海证券交易所报送相关文件之目的使用，不得用作其他任 何目的。 德勤华永会计师事务所(特殊普通合伙) 中国注册会计师 中国·上海 无锡药明康德新药开发股份有限公司（以下简称"本公司"）通过独特的 "CRDMO"（Contract Research Development and Manufacturi ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-006 无锡药明康德新药开发股份有限公司 第三届监事会第十一次会议暨 2024 年年度监事会会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 3 月 3 日及 2025 年 3 月 14 日向本公司全体监事发出会议通知及会议材 料，以现场结合通讯表决方式于 2025 年 3 月 17 日在公司会议室召开第三届监事 会第十一次会议暨 2024 年年度监事会会议。本次监事会会议应出席监事 3 人， 实际出席监事 3 人，会议由监事会主席 Harry Liang He（贺亮）主持。本次监事 会符合《中华人民共和国公司法》（以下简称"《公司法》"）和《无锡药明康德新 药开发股份有限公司章程》（以下简称"《公司章程》"）关于召开监事会会议 的规定。 二、监事会会议审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 同意《无锡药明康德新药 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-005 无锡药明康德新药开发股份有限公司 第三届董事会第十七次会议暨 2024 年年度董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 3 月 3 日及 2025 年 3 月 14 日向本公司全体董事发出会议通知及会议材 料，以现场结合通讯表决方式于 2025 年 3 月 17 日在公司会议室召开第三届董事 会第十七次会议暨 2024 年年度董事会会议。本次董事会会议应出席董事 12 人， 实际出席董事 12 人，会议由董事长 Ge Li（李革）主持。本次董事会符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《无锡药明康德新药开发股 份有限公司章程》（以下简称"《公司章程》"）关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 同意《无锡药明康德新药开发股份有限公司 2 ...

Financial Performance - Total revenue for 2024 was approximately CNY 39.24 billion, a decrease of 2.73% compared to CNY 40.34 billion in 2023 [25]. - Net profit attributable to shareholders for 2024 was approximately CNY 9.45 billion, down 1.63% from CNY 9.61 billion in 2023 [25]. - The net profit after deducting non-recurring gains and losses was approximately CNY 9.99 billion, an increase of 2.47% from CNY 9.75 billion in 2023 [25]. - The company's total assets increased by 9.04% to approximately CNY 80.33 billion at the end of 2024, compared to CNY 73.67 billion at the end of 2023 [25]. - The net assets attributable to shareholders increased by 6.37% to approximately CNY 58.63 billion at the end of 2024, compared to CNY 55.12 billion at the end of 2023 [25]. - Basic earnings per share for 2024 were CNY 3.28, a slight increase of 0.31% from CNY 3.27 in 2023 [26]. - The weighted average return on equity decreased to 16.78% in 2024, down 2.21 percentage points from 18.99% in 2023 [26]. - The net cash flow from operating activities for 2024 was approximately CNY 12.41 billion, a decrease of 7.32% from CNY 13.39 billion in 2023 [25]. - The company reported a total revenue of RMB 39.24 billion, a decrease of 2.73% compared to the previous year, with a gross profit of RMB 16.28 billion and a gross margin of 41.48% [52]. Dividend and Profit Distribution - The proposed cash dividend for the 2024 fiscal year is RMB 9.8169 per 10 shares, totaling RMB 2,835,113,437.82, which represents 30.00% of the net profit attributable to shareholders [6]. - The total amount for cash dividends and share repurchase is RMB 5,835,115,356.69, accounting for 61.75% of the net profit attributable to shareholders for the year [6]. - The average net profit over the last three accounting years was RMB 9,290,256,865.45, resulting in a cash dividend ratio of 122.35% [161]. - The company’s cash dividend policy aims to ensure a stable and sustainable return to investors, with a minimum cash distribution of 10% of the distributable profit for the year [154]. - The proposed profit distribution plan is subject to approval at the company’s shareholders' meeting [156]. - The company has maintained a positive profit distribution strategy, ensuring that cash dividends are aligned with its long-term development goals [154]. Market Expansion and Growth Strategy - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth [27]. - The company expects revenue from continuing operations to return to double-digit growth in 2025, with a year-on-year increase of 10%-15%, reaching RMB 41.5-43 billion [48]. - WuXi AppTec plans to expand its market presence in Europe, targeting a 30% increase in revenue from this region by 2025 [120]. - The company is investing RMB 1 billion in new product development, focusing on biologics and gene therapy technologies [120]. - The company is exploring potential acquisitions to enhance its service offerings, with a budget of $300 million allocated for this purpose [122]. Client and Order Growth - The company had approximately 6,000 active clients at the end of 2024, with 5,500 in ongoing operations and 1,000 new clients added during the year, reflecting a growing demand for services globally [36]. - The total orders in hand for ongoing operations reached RMB 49.31 billion, representing a year-on-year increase of 47.0% [36]. - Revenue from the top 20 global pharmaceutical companies amounted to RMB 16.64 billion, with a year-on-year growth of 24.1% after excluding specific commercial production projects [39]. - User data indicated a 25% increase in the number of active clients, totaling 1,500 clients by the end of 2024 [120]. Research and Development - The company’s R&D expenses decreased by 14.03% to RMB 1.24 billion, while investment income surged by 158.36% to RMB 604 million [51]. - Research and development expenses accounted for 10% of total revenue, amounting to RMB 2 billion in 2024 [120]. - The company has a total of 31,819 R&D personnel, accounting for 80.7% of the total workforce [64]. - The company has launched three new service platforms aimed at improving client engagement and operational efficiency [120]. Environmental Responsibility - The company invested approximately 17.03 million yuan in environmental protection during the reporting period [170]. - The company has established a waste management program to ensure compliance with national regulations, with hazardous waste being handled by qualified third-party companies [187]. - The company is committed to continuous improvement in environmental performance, as evidenced by its comprehensive reporting and management of emissions and waste [172]. - The company reported a total of 9.945 tons of COD emissions from wastewater discharge, with a concentration range of 23-70 mg/L, well below the limit of 500 mg/L [172]. Governance and Compliance - The company has established a robust internal control system to ensure compliance with national laws and regulations, although risks remain due to the number of subsidiaries [100]. - The company has maintained a fully independent operational capability, with no business dependencies or competitive relationships with enterprises controlled by the actual controller [113]. - The company has implemented a comprehensive human resources management system, ensuring that all directors and senior management are elected or appointed through legal procedures, with no interference from the controlling shareholder [112]. - The company has not faced any penalties from securities regulatory agencies in the past three years [132]. Financial Health and Stability - The company’s cash and cash equivalents increased to ¥18.32 billion, representing 22.81% of total assets, up from 18.68% in the previous period, reflecting a growth of 33.12% [70]. - The company reported a significant reduction in short-term borrowings, decreasing by 66.11% to ¥1.24 billion, down from ¥3.67 billion in the previous period [70]. - The total assets of the company increased by 10% to 15 billion RMB, indicating strong financial health and stability [124]. - The company’s long-term borrowings increased by 330.78% to ¥2.96 billion, compared to ¥687.02 million in the previous period [70].

关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年度利润分配方案，每 10 股派发现金红利人民币 9.8169 元（含税）。 此次利润分配方案以 2024 年度实施权益分派股权登记日的总股本为基 数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前公司 总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配总额， 并将另行公告具体调整情况。 此次利润分配方案未触及《上海证券交易所股票上市规则》（以下简称 "《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-007 无锡药明康德新药开发股份有限公司 一、利润分配方案内容 （一）2024 年度利润分配方案的具体内容 经德勤华永会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）2024 年度实现 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配方案：每 10 股派发现金红利人民币 3.5000 元（含税）。 此次回报股东特别分红方案以实施此次权益分派股权登记日的总股本 为基数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前 公司总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配 总额，并将另行公告具体调整情况。 一、特别分红方案 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2024 年 12 月 25 日公告通过其全资子公司 WuXi ATU (Ireland) Holding Limited、 WuXi ATU (Hong Kong) Limited 向 Altaris LLC（包括其所控制的主体）转让 WuXi ATU 业务的美国及英国运营主体的全部股权，并于 2025 年 3 月 7 日（美国时间） 完成交割。该部分业务的出售主要是为了确保所有迫切需要 WuXi ATU 细胞治 疗服务的客户和患者得到不受中断的服务和及时救治，同时 WuX ...

无锡药明康德新药开发股份有限公司 关于提请股东大会授权董事会制定中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）根据《中华人民 共和国公司法》《上市公司章程指引》《上市公司监管指引第 3 号——上市公司 现金分红》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相 关法律、法规、规范性文件及《无锡药明康德新药开发股份有限公司章程》规定， 为进一步提高分红频次，增强投资者回报水平，结合公司实际情况，公司董事会 提请股东大会授权董事会，在授权范围内制定并实施公司 2025 年中期分红方案， 具体安排如下： 一、2025 年中期现金分红安排 1、中期分红的前提条件为： （1）公司在当期盈利、累计未分配利润为正；（2）公司现金流可以满足正 常经营和持续发展的要求。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-009 1 公司于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董 事会会议和第三届监 ...

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 (1)建議變更本公司的註冊資本； 及 (2)建議修訂《公司章程》 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2019年8月5日的通 函（「該通函」）；及(ii)本公司於2023年5月26日、2024年3月8日、2024年5月23日、 2024年9月10日及2024年9月27日的公告（「該等公告」），內容有關（其中包括） (a)2019年A股激勵計劃調整後首次授予股票期權第三個行權期行權條件成就； 及(b)第二次及第三次回購本公司A股及該等回購註銷完成。除非文義另有所指， 否則該通函及該等公告所界定的詞語在本公告具有相同涵義。 本公司董事會（「董事會」）謹此宣佈，於2025年3月17日，董事會在第三屆董事 會第十七次會議上議決及批准（其中包括）建 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a revenue of RMB 39,241.4 million, a decrease of 2.7% compared to RMB 40,340.8 million in 2023[2]. - The net profit attributable to the parent company was RMB 9,352.6 million, down 12.5% from RMB 10,690.2 million in the previous year[2]. - Gross profit for the reporting period was RMB 16,016.1 million, a decrease of 2.2% year-on-year, with a gross margin of 40.8%[17]. - The adjusted net profit attributable to the parent company for the year ended December 31, 2024, was RMB 9,352.6 million, a decrease of 12.5% from RMB 10,690.2 million in 2023[41]. - The adjusted gross profit for the year ended December 31, 2024, was RMB 16,326.3 million, down 3.6% from RMB 16,937.8 million in 2023, with a gross margin of 41.6% compared to 42.0% in the previous year[41]. - The company reported a total comprehensive income of RMB 9,654,674 thousand for the year, down from RMB 10,884,792 thousand in the previous year[139]. - Basic earnings per share for the year was RMB 3.88, compared to RMB 3.83 for the previous year, indicating a marginal increase[137]. Customer and Market Insights - The company had approximately 6,000 active customers by the end of 2024, with 5,500 in continuing operations and 1,000 new customers added during the year[7]. - Revenue from the top 20 global pharmaceutical companies amounted to RMB 16.64 billion, with a year-on-year growth of 24.1% excluding COVID-19 commercialization projects[7]. - Revenue from U.S. customers was RMB 25.02 billion, a 7.7% increase excluding COVID-19 commercialization projects, while revenue from European customers grew by 14.4% to RMB 5.23 billion[7]. - The company has approximately 6,000 active clients as of the end of 2024, covering all of the top 20 global pharmaceutical companies[67]. Business Segments Performance - The company’s revenue from its chemistry business was RMB 29,052.4 million, a slight decrease of 0.4% from RMB 29,171.5 million in 2023[10]. - The testing business achieved revenue of RMB 56.7 billion, with TIDES business revenue reaching RMB 58.0 billion, a year-on-year increase of 70.1%[13]. - Clinical CRO and SMO business revenue was RMB 18.1 billion, a year-on-year increase of 2.8%, with SMO business growing by 15.4%[13]. - WuXi Biology generated revenue of RMB 25.4 billion, remaining stable year-on-year, with expectations for a 10%-15% growth in 2025[14]. Cash Flow and Investments - For the fiscal year ending December 31, 2024, the net cash generated from operating activities was RMB 11,986.8 million, a decrease of 5.2% compared to RMB 12,641.2 million for the fiscal year ending December 31, 2023[29]. - The net cash used in investing activities for the fiscal year ending December 31, 2024, was RMB (5,098.0) million, a decrease of 25.2% from RMB (6,817.0) million in the previous year, primarily due to timing differences in capital expenditures[29]. - The company made additional investments of RMB 12.2 million in joint ventures and associates during the reporting period to enhance synergies and expand its customer base[48]. - New investments outside of joint ventures and associates totaled RMB 372.1 million, with significant changes in the fair value of investments reported[50]. Dividends and Shareholder Returns - The company plans to distribute a final dividend of RMB 9.8169 per 10 shares, totaling RMB 2,835,113,437.82[3]. - A special dividend of RMB 3.5000 per 10 shares is proposed for 2025, amounting to RMB 1,010,797,403.70[4]. - The proposed cash dividend for 2024 is RMB 9.8169 per 10 shares, compared to RMB 9.8974 per 10 shares in 2023, indicating a slight decrease in the dividend payout[173]. Financial Position and Liabilities - As of December 31, 2024, total liabilities amounted to RMB 21,240.2 million, an increase from RMB 18,151.9 million as of December 31, 2023, with a debt-to-asset ratio of 26.4% compared to 24.6% in the previous year[32]. - The company reported a significant reduction in current bank borrowings, which decreased by 65.6% to RMB 1,278.6 million in 2024 from RMB 3,721.6 million in 2023[45]. - The total amount of liabilities related to derivative financial instruments decreased by 59.7% to RMB 202.0 million in 2024 from RMB 501.9 million in 2023[45]. Strategic Initiatives and Future Outlook - The company aims to enhance its capabilities and scale globally to empower pharmaceutical innovation[63]. - The company is focused on attracting and retaining top talent by reforming its reward and incentive systems, providing real promotion opportunities, and offering competitive compensation packages[97]. - The company will continue to invest heavily in new drug development technologies, focusing on various new molecular types such as peptides, oligonucleotides, PROTACs, and conjugated drugs[95]. - The overall revenue forecast for 2025 is projected to be between RMB 415 billion and RMB 430 billion[14]. Risks and Challenges - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could negatively impact its business if industry growth slows or outsourcing ratios decrease[101]. - The company is exposed to regulatory risks due to the highly regulated nature of the pharmaceutical R&D services industry, requiring timely adjustments to its business strategies[102]. - The company acknowledges the increasing competition in the global pharmaceutical R&D services market, which may weaken its competitive advantages if not addressed[104].